TG Therapeutics, Inc. $TGTX Shares Bought by Algert Global LLC

Key Points

• Algert Global LLC increased its stake in TG Therapeutics, Inc. by 57.0% during the first quarter, owning a total of 77,041 shares valued at approximately $3 million.
• Several institutional investors, including Allspring Global Investments and New York State Teachers Retirement System, also significantly boosted their holdings in the company during the same period, indicating strong institutional interest.
• TG Therapeutics reported a revenue increase of 92.1% year-over-year, though it missed earnings expectations, posting $0.17 EPS against a consensus estimate of $0.32 EPS.

Algert Global LLC boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 57.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 77,041 shares of the biopharmaceutical company's stock after purchasing an additional 27,980 shares during the quarter. Algert Global LLC's holdings in TG Therapeutics were worth $3,038,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of TGTX. Envestnet Asset Management Inc. increased its holdings in TG Therapeutics by 11.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 50,111 shares of the biopharmaceutical company's stock worth $1,508,000 after purchasing an additional 5,135 shares during the period. XTX Topco Ltd purchased a new position in shares of TG Therapeutics in the 4th quarter valued at about $400,000. NewEdge Advisors LLC increased its holdings in shares of TG Therapeutics by 4,549.7% in the 4th quarter. NewEdge Advisors LLC now owns 6,928 shares of the biopharmaceutical company's stock valued at $209,000 after acquiring an additional 6,779 shares during the last quarter. Commerce Bank purchased a new position in shares of TG Therapeutics in the 4th quarter valued at about $204,000. Finally, First Trust Advisors LP increased its holdings in shares of TG Therapeutics by 871.7% in the 4th quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company's stock valued at $8,292,000 after acquiring an additional 247,145 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.64% of the company's stock.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded down $0.25 during trading hours on Tuesday, reaching $28.28. The stock had a trading volume of 1,551,290 shares, compared to its average volume of 2,905,861. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 76.43 and a beta of 1.95. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a fifty-two week low of $21.11 and a fifty-two week high of $46.48. The firm has a 50-day moving average of $33.82 and a 200-day moving average of $35.64.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same period in the previous year, the business posted $0.04 earnings per share. The firm's revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.